Medpace Holdings, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Medpace Holdings, Inc. (MEDP) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of -$40.85 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-10
- Medpace Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was -$40.85M.
- Medpace Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was -$22.20M.
- Medpace Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was -$14.69M.
- Medpace Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was -$18.74M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|---|
| 2025-12-31 | -$40.85M 10-K · filed 2026-02-10 | |
| 2024-12-31 | -$22.20M 10-K · filed 2026-02-10 | |
| 2023-12-31 | -$14.69M 10-K · filed 2026-02-10 | |
| 2022-12-31 | -$18.74M 10-K · filed 2025-02-11 | |
| 2021-12-31 | -$19.04M 10-K · filed 2024-02-13 | |
| 2020-12-31 | -$10.02M 10-K · filed 2023-02-14 | |
| 2019-12-31 | -$3.01M 10-K · filed 2022-02-15 | |
| 2018-12-31 | -$651.00K 10-K · filed 2021-02-16 | |
| 2017-12-31 | -$179.00K 10-K · filed 2020-02-25 | |
| 2016-12-31 | -$534.00K 10-K · filed 2019-02-26 | |
| 2015-12-31 | $778.00K 10-K · filed 2017-02-28 | |
| 2014-12-31 | $332.00K 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |